May 22, 2019 07:19 AM EDTUpdated 09:39 AM
R&D

No­var­tis drums up an­tic­i­pa­tion for block­buster-to-be with PhII da­ta on asth­ma drug, beat­ing Ad­vair in head-to-head

Amber Tong

An asth­ma drug that No­var­tis has tapped as a big mon­ey­mak­er has de­liv­ered a clean sweep in Phase II, boost­ing its block­buster case months ahead …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Ax­some moves to­ward NDA fil­ing for nar­colep­sy drug fol­low­ing pos­i­tive Phase 3 da­ta

Soleno’s rare pe­di­atric dis­ease drug faces PDU­FA de­lay by three months

Ag­i­lent re­veals plans to re­mod­el op­er­a­tions as an­nu­al rev­enue dips

A service from the Financial Times